MUC1 mucin in urological malignancy
2003; Wiley; Volume: 91; Issue: 6 Linguagem: Italiano
10.1046/j.1464-410x.2003.04132.x
ISSN1464-410X
AutoresDavid Scholfield, Matthew Simms, M.C. Bishop,
Tópico(s)Cholangiocarcinoma and Gallbladder Cancer Studies
ResumoBJU InternationalVolume 91, Issue 6 p. 560-566 MUC1 mucin in urological malignancy D.P. Scholfield, D.P. Scholfield Department of Urology, City Hospital, Nottingham, UKSearch for more papers by this authorM.S. Simms, M.S. Simms Department of Urology, City Hospital, Nottingham, UKSearch for more papers by this authorM.C. Bishop, M.C. Bishop Department of Urology, City Hospital, Nottingham, UKSearch for more papers by this author D.P. Scholfield, D.P. Scholfield Department of Urology, City Hospital, Nottingham, UKSearch for more papers by this authorM.S. Simms, M.S. Simms Department of Urology, City Hospital, Nottingham, UKSearch for more papers by this authorM.C. Bishop, M.C. Bishop Department of Urology, City Hospital, Nottingham, UKSearch for more papers by this author First published: 26 March 2003 https://doi.org/10.1046/j.1464-410X.2003.04132.xCitations: 8 D.P. Scholfield, Department of Urology, City Hospital, Hucknall Road, Nottingham, UK. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Williams SJ, McGukin MA, Gotley DC et al. Two novel mucin genes down-regulated in colorectal cancer identified by differential display. Cancer Res 1999; 59: 4083–9 CASPubMedWeb of Science®Google Scholar 2 Moniaux N, Escande F, Porchet N, Aubert JP, Batra SK. Structural organisation and classification of the mucin genes. Front Biosci 2001; 6: D1192–206 10.2741/Moniaux CASPubMedWeb of Science®Google Scholar 3 Taylor-Papdimitriou J, Peterson J, Arklie J, Burchell J, Ceriani R, Bodmer W. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 1981; 28: 17–21 10.1002/ijc.2910280104 PubMedWeb of Science®Google Scholar 4 Shimiza M, Yamauchi K. Isolation and characterisation of mucin-like glycoprotein inhuman milk fat globule membrane. J Biochem 1982; 91: 515–24 PubMedWeb of Science®Google Scholar 5 Croghan GA, Papsidero LD, Valenzuela LA, Nemoto T, Penetrante R, Chu TM. Tissue distribution of an epithelial and tumour-associated recognised by monoclonal antibody F36/22. Cancer Res 1983; 43: 4980–8 CASPubMedWeb of Science®Google Scholar 6 McGee J O’D, Woods JC, Ashall F, Bramwell ME, Harris H. A new marker for human cancer cells. Immunohistochemical detection of the Ca antigen in human tissues with the Ca 1 antibody. Lancet 1982; ii: 7–10 10.1016/S0140-6736(82)91151-5 CASGoogle Scholar 7 Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J. Tissue and tumour distribution of human polymorphic epithelial mucin. Cancer Rev 1988; 11–12: 55–101 Google Scholar 8 Hilkens J, Buijs F, Hilgers J et al. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumours. Int J Cancer 1984; 34: 197–206 10.1002/ijc.2910340210 CASPubMedWeb of Science®Google Scholar 9 Price MR, Pugh JA, Hudecz F et al. C595 – a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer 1990; 61: 681–6 10.1038/bjc.1990.154 CASPubMedWeb of Science®Google Scholar 10 Dong Y, Walsh M, Cummings M, Wright R et al. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 1997; 183: 311–7 10.1002/(SICI)1096-9896(199711)183:3 3.0.CO;2-2 CASPubMedWeb of Science®Google Scholar 11 Ho SB, Niehans GA, Lyftogt C et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993; 53: 641–51 CASPubMedWeb of Science®Google Scholar 12 Price MR, Hudecz F, O'Sullivan C, Baldwin RW, Edwards PM, Tendler SJB. Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunol 1990; 27: 795–802 10.1016/0161-5890(90)90089-I CASPubMedWeb of Science®Google Scholar 13 Ligtenberg MJ, Vos HL, Gennisen AM, Hilkens J. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternate amino termini. J Biol Chem 1990; 265: 5573–8 CASPubMedWeb of Science®Google Scholar 14 Muller S, Goletz S, Packer N, Gooley A, Lawson A, Hanisch F-G. Localisation of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1. J Biol Chem 1997; 272: 9707–19 10.1074/jbc.272.40.24780 Web of Science®Google Scholar 15 Burchell J, Poulson R, Hanby A et al. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glyobiology 1999; 9: 1307–11 10.1093/glycob/9.12.1307 CASPubMedWeb of Science®Google Scholar 16 Braga V, Pemberton L, Duhig T, Gendler S. Spatial and temporal expression of an epithelial mucin, MUC1, during mouse development. Development 1992; 115: 427–37 CASPubMedWeb of Science®Google Scholar 17 Hudson MJ, Stamp GW, Chaudhary KS et al. Human MUC1 mucin: a powerful glandular morphogen. J Pathol 2001; 194: 373–83 10.1002/1096-9896(200107)194:3 3.0.CO;2-6 CASPubMedWeb of Science®Google Scholar 18 Patton S. The epithelial mucin, MUC1, of milk, mammary gland and other tissues. Biochim Biophysica Acta 1995; 1241: 407–24 10.1016/0304-4157(95)00014-3 PubMedWeb of Science®Google Scholar 19 Li Y, Kuwahara H, Ren J, Wen G, Kufe D. The c-Src tyrosine kinase regulates signalling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem 2001; 276: 6061–4 10.1074/jbc.C000754200 CASPubMedWeb of Science®Google Scholar 20 Gendler SJ. MUC1 the renaissance molecule. J Mammary Gland Biol Neoplasia 2001; 6: 339–53 10.1023/A:1011379725811 CASPubMedWeb of Science®Google Scholar 21 Schroeder JA, Thompson MC, Gardner MM, Gendler SJ. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001; 276: 13057–64 10.1074/jbc.M011248200 CASPubMedWeb of Science®Google Scholar 22 Meerzaman D, Shapiro PS, Kim KC. Involvement of the MAP kinase ERK2 in MUC1 mucin cell signalling. Am J Physiol Lung Cell Mol Physiol 2001; 281: L86–91 10.1152/ajplung.2001.281.1.L86 CASPubMedWeb of Science®Google Scholar 23 Li Y, Ren J, Yu W et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta catenin. J Biol Chem 2001; 276: 35239–42 10.1074/jbc.C100359200 CASPubMedWeb of Science®Google Scholar 24 Li Y, Kufe D. The human DF3/MUC1 carcinoma associated antigen signals nuclear localisation of the catenin p120. Biochem Biophys Res Comm 2001; 281: 440–3 10.1006/bbrc.2001.4383 CASPubMedWeb of Science®Google Scholar 25 Hilkens J, Ligtenberg JL, Vos HL, Litvinov S. Cell membrane associated mucins and their adhesion-modulating property. Trends Biochem Sci 1992; 17: 359–63 10.1016/0968-0004(92)90315-Z CASPubMedWeb of Science®Google Scholar 26 Ligtenberg MJL, Buijs F, Vos HL, Hilkens J. Suppression of cellular aggregation by high levels of episialin. Cancer Res 1992; 52: 2318–24 CASPubMedWeb of Science®Google Scholar 27 Van Klinken BJ-W, Dekker J, Buller H, Einerhand A. Mucin gene structure and expression: protection vs. adhesion. Am J Physiol 1995; 269: 613–27 CASPubMedWeb of Science®Google Scholar 28 Wesseling J, Van Der Walk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996; 7: 565–77 10.1091/mbc.7.4.565 CASPubMedWeb of Science®Google Scholar 29 Kondo K, Kohno N, Yokoyama A et al. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res 1998; 58: 2014–9 CASPubMedWeb of Science®Google Scholar 30 Schwartz B, Bresalier RS, Young KS. The role of mucin in colon cancer metastasis. Int J Cancer 1992; 52: 60–5 10.1002/ijc.2910520113 CASPubMedWeb of Science®Google Scholar 31 Regimbald LH, Pilarski LM, Longenecker M et al. The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 1996; 56: 4244–9 CASPubMedWeb of Science®Google Scholar 32 Van de Wiel–van Kemenade E, Ligtenberg MJL, De Boer AJ et al. Episialin (MUC1) inhibits cytotoxic lymphocyte–target cell interaction. J Immunol 1993; 151: 767–76 CASPubMedWeb of Science®Google Scholar 33 Agrawal B, Krantz MJ, Reddish MA, Longenecker M. Cancer associated MUC1 mucin inhibits human t-cell proliferation which is reversible by IL2. Nature Med 1998; 4: 43–9 10.1038/nm0198-043 CASPubMedWeb of Science®Google Scholar 34 McGuckin MA, Walsh MD, Hohn BG et al. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 1995; 26: 432–9 10.1016/0046-8177(95)90146-9 CASPubMedWeb of Science®Google Scholar 35 Spicer AP, Rowse GJ, Linder TK, Gendler SJ. Delayed mammary tumour progression in MUC1 null mice. J Biol Chem 1995; 270: 30093–101 10.1074/jbc.270.50.30093 CASPubMedWeb of Science®Google Scholar 36 Hiraga Y, Tanaka S, Haruma K et al. Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 1998; 55: 307–19 10.1159/000011868 CASPubMedWeb of Science®Google Scholar 37 Kimura T, Tanaka S, Haruma K et al. Clinical significance of MUC1 and E- cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol 2000; 16: 55–64 CASPubMedWeb of Science®Google Scholar 38 Ohgami A, Tsuda T, Osaki T et al. MUC1 mucin RNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thoracic Surg 1999; 67: 810–4 10.1016/S0003-4975(99)00041-7 CASPubMedWeb of Science®Google Scholar 39 Guddo F, Giatromanolaki A, Koukourakis MI et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998; 51: 667–71 10.1136/jcp.51.9.667 CASPubMedWeb of Science®Google Scholar 40 Cao YK, Zerban H, Bannasch P. Expression of MUC1, Thomsen-Friedenreich-related antigens, and cytokeratin 19 in human renal cell carcinomas and tubular clear cell lesions. Virchows Arch 2000; 436: 119–26 10.1007/PL00008210 CASPubMedWeb of Science®Google Scholar 41 Fujita K, Denda K, Yamamoto M, Matsumoto T, Fujime M, Irimura T. Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. Br J Cancer 1999; 80: 301–8 10.1038/sj.bjc.6690355 CASPubMedWeb of Science®Google Scholar 42 Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1988; 4: 295–302 Google Scholar 43 Kirschenbaum A, Itzkowitz SH, Wang JP, Yao S, Eliashvili M, Levine AC. MUC1 expression in prostate carcinoma. correlation with grade and stage. Mol Urol 1999; 3: 163–8 PubMedWeb of Science®Google Scholar 44 Kraus S, Linsenmann H-J, Nachtmann C et al. The mucin glycoprotein MUC1 and members of the trefoil factor family in prostate carcinoma. Eur Urol 1999; 35 (Suppl. 2): 75 Google Scholar 45 Mitchell SE, Abel PD, Chaudory KS, Stamp GWH, Lalani EN. Androgen-dependent regulation of MUC1 expression in prostate cancer. BJU Int 2000; 85 (Suppl. 5): 10 Google Scholar 46 Mitchell S, Abel P, Ware M, Stamp G, Lalani E. Phenotypic and genotypic characterisation of commonly used prostatic cell lines. BJU Int 2000; 85: 932–44 10.1046/j.1464-410x.2000.00606.x CASPubMedWeb of Science®Google Scholar 47 Devine PL, McGuckin MA, Ramm LE et al. Serum mucin antigens, CASA and MSA in tumours of the breast, ovary, lung pancreas, bladder, colon and prostate. Cancer 1993; 72: 2007–15 10.1002/1097-0142(19930915)72:6 3.0.CO;2-U CASPubMedWeb of Science®Google Scholar 48 Takashi M, Murase T, Kinjo T, Mitsuya H, Nagura H. Epithelial membrane antigen as an immunohistochemical marker for transitional cell carcinoma of the urinary bladder. Urol Int 1987; 42: 170–5 10.1159/000281888 PubMedWeb of Science®Google Scholar 49 Walsh MD, Hohn BG, Thong W et al. Mucin expression by transitional cell carcinomas of the bladder. Br J Urol 1994; 73: 256–62 10.1111/j.1464-410X.1994.tb07514.x CASPubMedWeb of Science®Google Scholar 50 Hughes O, Denley H, Kunkler R et al. MUC1 mucin expression in transitional cell carcinoma of the bladder: a target for diagnosis and therapy with monoclonal antibody C595. J Urol Pathol 2000; 12: 185–97 10.1385/JUP:12:3:179 Google Scholar 51 Conn IG, Crocker J, Emtage LA, Wallace DMA. HMFG-2 as a prognostic indicator in superficial bladder cancer. J Clin Pathol 1988; 41: 1191–5 10.1136/jcp.41.11.1191 PubMedWeb of Science®Google Scholar 52 Robertson JF, Jaeger W, Syzmendera JJ et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer 1999; 35: 47–53 10.1016/S0959-8049(98)00297-4 CASPubMedWeb of Science®Google Scholar 53 Simms M, Hughes O, Limb M, Price M, Bishop, M. MUC1 mucin as a tumour marker in bladder cancer. BJU Int 1999; 84: 350–2 10.1046/j.1464-410x.1999.00150.x CASPubMedWeb of Science®Google Scholar 54 Barnd DL, Lans MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumour-associated mucins by cytotoxic T cells. Proc Natl Acad Sci USA 1989; 86: 7159–63 10.1073/pnas.86.18.7159 CASPubMedWeb of Science®Google Scholar 55 Gendler S, Taylor-Papadimitrou J, Duhig T, Rothbard J, Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 1988; 263: 12820–3 CASPubMedWeb of Science®Google Scholar 56 Jerome KR, Barnd DL, Bendt KM et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinomas recognise an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991; 51: 2908–16 CASPubMedWeb of Science®Google Scholar 57 Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumour-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci 1989; 86: 7159–63 10.1073/pnas.86.18.7159 CASPubMedWeb of Science®Google Scholar 58 Rughetti A, Turchi V, Ghetti CA et al. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 1993; 53: 2457–9 CASPubMedWeb of Science®Google Scholar 59 Von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P et al. Humoral immune response to polymorphic epithelial mucin (MUC-1)-containing circulating complexes in carcinoma patients. Br J Cancer 1995; 72: 934–8 10.1038/bjc.1995.436 PubMedWeb of Science®Google Scholar 60 Malamitsi J, Zorzos J, Varvarigou A et al. Immmunolocalization of transitional cell carcinoma with intravesically administered technetium-99m labelled HMFG1 monoclonal antibody. Eur J Nucl Med 1995; 22: 25–31 10.1007/BF00997244 CASPubMedWeb of Science®Google Scholar 61 Kunkler RB, Bishop MC, Green DJ, Pimm MV, Price MR, Frier M. Targeting of bladder cancer with monoclonal antibody NCRC48-a possible approach for intravesical therapy. Br J Urol 1995; 76: 81–6 10.1111/j.1464-410X.1995.tb07837.x CASPubMedWeb of Science®Google Scholar 62 Hughes O, Perkins A, Frier M et al. Imaging for staging bladder cancer. A clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. BJU Int 2001; 87: 39–46 10.1046/j.1464-410x.2001.00985.x CASPubMedWeb of Science®Google Scholar 63 Moase EH, Qi W, Ishida T et al. Anti-MUC1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophys Acta 2001; 1510: 43–55 10.1016/S0005-2736(00)00334-5 CASPubMedWeb of Science®Google Scholar 64 Hughes O, Bishop M, Perkins A, Frier M et al. Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer. Eur J Nucl Med 1997; 24: 439–43 CASPubMedWeb of Science®Google Scholar 65 Hughes O, Bishop M, Perkins A et al. Targetting superficial bladder cancer by the intravesical administration of 67copper-labelled anti-MUC1 mucin monoclonal antibody C595. J Clin Oncol 2000; 18: 363–70 10.1200/JCO.2000.18.2.363 CASPubMedWeb of Science®Google Scholar 66 Murray A, Simms M, Scholfield D, Vincent R et al. Production and characterization of rhenium-188-C595 antibody for radioimmunotherapy of transitional cell bladder cancer. J Nucl Med 2001; 42: 726–32 CASPubMedWeb of Science®Google Scholar 67 Syrigos K, Karaiannakis A, Zbar A. Mucins as immunogenic targets in cancer. Anticancer Res 1999; 19: 5239–44 CASPubMedWeb of Science®Google Scholar 68 Brossart P, Heinrich K, Stuhler G, Behnke L et al. Identification of HLA-A2-restricted T-Cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999; 12: 4309–17 Google Scholar 69 Graham R, Burchell J, Taylor-Papadimitriou J. The polymorphic epithelial mucin as an immunogen for a cancer vaccine. Cancer Immunol Immunother 1996; 42: 71–80 10.1007/s002620050254 CASPubMedWeb of Science®Google Scholar 70 Goydos JS, Elder E, Whiteside TE, Finn OJ, Lotze MT. A phase 1 trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996; 63: 298–304 10.1006/jsre.1996.0264 CASPubMedWeb of Science®Google Scholar 71 Reddish MA, Maclean GD, Poppema S, Berg A, Longnecker BM. Pre-immunotherapy serum CA27.29 (MUC1) mucin level and CD69+ lymphocytes correlate with effects of theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother 1996; 42: 303–9 10.1007/s002620050287 CASPubMedWeb of Science®Google Scholar 72 Slovin S, Livingston P, Rosen N et al. Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Semin Oncol 1996; 23 (Suppl. 14): 41–8 CASPubMedWeb of Science®Google Scholar 73 Slovin S, Kelly W, Scher H. Immunological approaches for the treatment of prostate cancer. Semin Urol Oncol 1998; 16: 53–9 CASPubMedGoogle Scholar 74 Graham RA, Burchell JM, Beverley P, Taylor-Papadimitriou J. Inntramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 1996; 65: 664–70 10.1002/(SICI)1097-0215(19960301)65:5 3.0.CO;2-7 CASPubMedWeb of Science®Google Scholar 75 Johnen H, Kulbe H, Pecher G. Long-term tumour growth suppression in mice immunized with naked DNA of the human tumour antigen (MUC1). Cancer Immunol Immunother 2001; 50: 356–6 10.1007/s002620100212 CASPubMedWeb of Science®Google Scholar 76 Scholl SM, Balloul JM, Le Goc G et al. Recombinant vaccinia virus encoding human MUC1 and IL-2 as immunotherapy in patients with breast cancer. J Immunol 2000; 23: 570–80 CASWeb of Science®Google Scholar 77 Barratt Boyes S, Vlad A, Finn O. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clin Cancer Res 1999; 5: 1918–24 CASPubMedWeb of Science®Google Scholar 78 Acres B, Apostolopoulos V, Balloul A et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various MUC1 vaccines. Cancer Immunol Immunother 2000; 48: 588– 94 10.1007/PL00006677 CASPubMedWeb of Science®Google Scholar 79 Vaughan H, Ho D, Karanikas V et al. Induction of humoral and cellular responses in Cynomolgus monkeys immunised with mannan-human MUC1 conjugates. Vaccine 1999; 17: 2740–52 10.1016/S0264-410X(98)00493-9 CASPubMedWeb of Science®Google Scholar 80 Akagi J, Hodge J, McLaughlin J et al. Therapeutic antitumour response after immunization with an admixture of recombinant vaccinia virus expressing a modified MUC1 gene and the murine T-cell co-stimulatory molecule B7. J Immunother 1997; 20: 38–47 10.1097/00002371-199701000-00004 CASPubMedWeb of Science®Google Scholar 81 Kugler A, Seseke F, Thelen P et al. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. BJU Int 1998; 82: 487–93 10.1046/j.1464-410X.1998.00794.x CASPubMedWeb of Science®Google Scholar 82 Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma with tumour cell-dendritic cell hybrids. Nature Med 2000; 6: 332–6 10.1038/73193 CASPubMedWeb of Science®Google Scholar 83 Sanda M, Ayyagari S, Jaffee E et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994; 151: 622–8 10.1016/S0022-5347(17)35032-2 CASPubMedWeb of Science®Google Scholar 84 Kontani K, Taguchi O, Narita T, Izawa M, Hiraiwa N, Zenita K. Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer 2001; 84: 1258–64 10.1054/bjoc.2000.1744 CASPubMedWeb of Science®Google Scholar Citing Literature Volume91, Issue6April 2003Pages 560-566 ReferencesRelatedInformation
Referência(s)